Home / Stocks / Bilcare Ltd.
BI

Bilcare Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹80.38

Change

-1.69 (-2.06%)

Open

₹82.48

Prev. Close

₹82.07

Day High

₹83.89

Day Low

₹79.8

Volume Analysis

Traded

6,913

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (3)

  • •High debt-to-equity ratio (3.64)
  • •Low return on equity (1.39%)
  • •Below-average fundamentals quality score (29/100)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹87.01 ₹85.45 ₹82.92 ₹81.36 ₹78.83 ₹77.27 ₹74.74
Fibonacci ₹85.45 ₹83.89 ₹82.92 ₹81.36 ₹79.8 ₹78.83 ₹77.27
Camarilla ₹81.5 ₹81.13 ₹80.75 ₹81.36 ₹80.01 ₹79.63 ₹79.26

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-0.04%

1 Month

-7.69%

3 Months

-14.18%

6 Months

+25.53%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹35.33

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

8.79%

Net margin 2.14% × asset turnover 0.84x × equity multiplier 4.89x

Company Overview

Sector

Healthcare

Market Cap

₹202 Cr

P/E (TTM)

5.55

ROE

1.39%

Book Value

₹76.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Bilcare Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 29/100. The strongest factor is Cash Flow (74/100), while Financial Strength (0/100) is the weakest area to weigh before deciding. Notably: High debt-to-equity ratio (3.64); low return on equity (1.39%).

TopFund Score — Fundamentals Quality

29/100 — Weak

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

0

Growth

5

Valuation

38

Cash Flow

74

Corporate Governance

40

Momentum

55

Institutional Ownership

30

Business Quality

23

Risk & Volatility

53

Liquidity

0

From Screener.in

  • +Stock is trading at 1.10 times its book value
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of 3.33% over past five years.
  • −Promoter holding is low: 30.0%
  • −Company has a low return on equity of -2.83% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Bilcare Limited the exchange about the Newspaper Publication of Un-Audited (Standalone and Consolidated) Financial Results for quarter and half ended 30 September 2026

Bilcare approved H1 FY27 results and appointed Mohan Bhandari Chairman effective 3 November 2026.

Bilcare Inc US, a wholly owned non-material subsidiary, dissolved effective 9 September 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 190 175 200 194 202 198 194 186 178 181 188 226 248
Expenses + 173 158 208 175 194 187 186 175 175 168 171 189 226
Operating Profit 17 17 -8 19 8 11 8 11 3 13 17 37 22
OPM % 8.79% 9.86% -4.13% 9.76% 3.79% 5.38% 3.96% 5.94% 1.92% 7.18% 9.02% 16.39% 8.98%
Other Income + 1 4 9 4 -6 -6 21 6 4 3 12 0 4
Interest 20 21 23 21 24 19 19 19 19 17 18 18 20
Depreciation 10 11 13 12 11 12 5 12 5 5 5 4 4
Profit before tax -13 -10 -35 -10 -33 -27 6 -13 -17 -6 7 15 2
Tax % -5.36% 34.06% -44.48% 55.01% -9.55% -39.92% -119.27% -24.69% -1.38% 3.33% -13.44% -0.88% 45.96%
Net Profit + -12 -14 -20 -15 -30 -16 12 -10 -16 -6 8 15 1
EPS in Rs -3 -3 -5 -3 -7 -3 7 -2 -2 0 6 5 2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -25 -29 -14 7 6 13 -3 -4 -12 -8 -3 21 39

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 2,692 2,603 2,633 2,778 2,997 1,827 623 845 982 747 788 734 843
Expenses + 2,506 2,396 2,443 2,617 2,827 1,782 572 784 925 708 742 689 754
Operating Profit 186 207 190 161 170 45 51 60 57 39 46 45 89
OPM % 7.0% 8.0% 7.0% 6.0% 6.0% 2.5% 8.0% 7.0% 6.0% 5.0% 6.0% 6.0% 11.0%
Other Income + 9 -87 107 297 59 254 45 44 237 16 12 26 19
Interest 236 151 176 249 283 174 76 69 60 82 83 72 73
Depreciation 191 164 177 416 378 239 46 39 38 45 18 20 18
Profit before tax -232 -194 -56 -207 -433 -114 -25 -4 196 -72 -43 -21 18
Tax % -7.0% -58.0% 42.0% -4.0% 5.0% -13.0% -55.0% 3.0% 74.0% -18.0% -35.0% -19.0% —
Net Profit + -216 -82 -80 -199 -453 -99 -11 -4 50 -59 -28 -17 18
EPS in Rs -92 -36 -36 -85 -193 -44 -9 -5 6 -14 0 1 13
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth -12 -3 1 6 8 -39 -66 36 16 -24 5 -7 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 1,073 689 590 376 -93 85 63 52 507 474 191 173 155
Borrowings + 2,311 2,122 2,014 2,089 2,270 707 677 690 639 756 689 620 652
Other Liabilities + 933 786 830 913 888 297 300 362 424 314 21 26 44
Total Liabilities 4,340 3,620 3,457 3,402 3,087 1,112 1,064 1,127 1,593 1,568 924 843 875
Fixed Assets + 1,926 2,432 2,403 2,180 2,005 534 494 465 1,045 1,038 456 432 406
CWIP 218 161 149 170 79 0 0 1 1 1 4 10 8
Investments 0 1 0 1 0 0 0 0 2 8 11 14 14
Other Assets + 2,196 1,026 904 1,051 1,003 577 570 661 545 521 453 387 447
Total Assets 4,340 3,620 3,457 3,402 3,087 1,112 1,064 1,127 1,593 1,568 924 843 875
Equity Capital 24 24 24 24 24 24 24 24 24 24 24 24 24

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -315 177 300 98 206 256 72 41 -7 62 86 128
Cash from Investing Activity + 247 -358 -129 -203 -104 1,309 2 -4 36 -106 81 -5
Cash from Financing Activity + 119 149 -155 91 -103 -1,600 -83 -55 -19 36 -171 -132
Net Cash Flow 50 -32 16 -13 -1 -35 -9 -18 10 -7 -3 -10
Free Cash Flow -74 -12 165 -115 91 1,569 69 37 11 -34 142 120
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -170 85 173 75 148 828 141 78 -6 162 192 283

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 30.01% → 30.01%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 69.95% 69.95% 69.95% 69.95% 69.95% 69.95% 69.95% 69.94% 69.95% 69.95% 69.94% 69.95%
Promoters 30.01% 30.01% 30.01% 30.01% 30.01% 30.01% 30.01% 30.01% 30.01% 30.01% 30.01% 30.01%
FII 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Bilcare Ltd. (this stock) 202 5.55 1.13 1.39%
Brooks Lab Limited 203 58.7 1.08 22.0%
Nectar Lifesciences Ltd. 193 — 0.34 -31.3%
Take Limited 192 22.0 5.6 16.5%
Balaxi Pharma Ltd 175 51.8 0.69 0.59%
Makers Laboratories Ltd. 169 22.6 2.15 3.17%
Natural Capsules Limited 144 — 0.66 -9.45%

Which Mutual Funds Hold Bilcare Ltd.?

Frequently Asked Questions about Bilcare Ltd.

Community Sentiment

What are other investors saying about Bilcare Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.